Update from ASCO 2023: Late-Breaking RCC Data
Update from ASCO 2023: Late-Breaking RCC Data
Prof. Thomas Powles shares his perspective on key RCC data
Prof. Thomas Powles shares his perspective on key RCC data
Prof. Thomas Powles
Medical Oncologist Prof. Thomas Powles discusses key RCC data from the CONTACT-03, KEYNOTE-426 and CLEAR trials presented at ASCO 2023, and shares his views on the implications for clinical practice.
Watch the short video and download the accompanying slides for your reference.
Prof. Thomas Powles
Medical Oncologist
Bart's Cancer Centre
United Kingdom (UK)
Video | 
3 min
|
Jun 2023
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Clinical Takeaways
-
CONTACT-03: For patients with mRCC, adding the atezolizumab to cabozantinib did not improve clinical outcomes compared with treatment with cabozantinib alone and higher toxicities were also observed in the combination arm
-
KEYNOTE-426: Pembrolizumab + axitinib continued to demonstrate improved OS, PFS, and ORR versus sunitinib for patients with previously untreated clear cell RCC and no new safety signals were observed
-
CLEAR: The combination of lenvatinib plus pembrolizumab remains superior to sunitinib on clinical outcomes as first-line treatment for advanced renal cell carcinoma after 4-years follow-up with no new safety signals detected
-
Long-term follow up data from KEYNOTE-426 and the CLEAR trial re-confirms current clinical practice of frontline combination immunotherapy/TKI for IDMC intermediate/poor risk patients
This educational programme is supported by an Independent Medical Education Grant from Eisai Europe Limited
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
2 min
Other programmes developed by Prof. Thomas Powles
Prof. Thomas Powles
Medical Oncologist
Bart's Cancer Centre
United Kingdom (UK)
